Constitutively active mutant KRas displays a reduced rate of GTP hydrolysis via both intrinsic and GTPase-activating protein-catalyzed mechanisms, resulting in the perpetual activation of Ras pathways. We describe a fragment screening campaign using X-ray crystallography that led to the discovery of three fragment binding sites on the Ras:SOS complex. The identification of tool compounds binding at each of these sites allowed exploration of two new approaches to Ras pathway inhibition by stabilizing or covalently modifying the Ras:SOS complex to prevent the reloading of Ras with GTP. Initially, we identified ligands that bound reversibly to the Ras:SOS complex in two distinct sites, but these compounds were not sufficiently potent inhibitor...
The RAS family of small GTPases, consisting of HRAS, KRAS and NRAS, represent the most frequently mu...
The RAS gene family is frequently mutated in human cancers, and the quest for compounds that bind to...
The RAS gene family is frequently mutated in human cancers, and the quest for compounds that bind to...
Constitutively active mutant KRas displays a reduced rate of GTP hydrolysis via both intrinsic and G...
AbstractThree decades after identification of the Ras oncogene, no effective treatments for Ras muta...
Somatic mutations in the small GTPase K-Ras are the most common activating lesions found in human ca...
Ral (Ras-like) GTPases are directly activated by oncogenic Ras GTPases. Mutant K-Ras (G12C) has enab...
SummaryRas GTPases regulate intracellular signaling involved in cell proliferation. Elevated Ras sig...
Despite more than three decades of intense effort, no anti-Ras therapies have reached clinical appli...
Covalent inhibitors of K-Ras(G12C) have been reported that exclusively recognize the GDP state. Here...
Ras is at the hub of signal transduction pathways controlling cell proliferation and survival. Its m...
Mutations in RAS are associated with many different cancers, and RAS has been a therapeutic target f...
Undruggability of RAS proteins has necessitated alternative strategies for the development of effect...
The activity of Ras is controlled by the inter-conversion between GTP- and GDP-bound forms, partly r...
The small GTPase K-Ras is the most frequently mutated oncogene in cancer, and its high nucleotide af...
The RAS family of small GTPases, consisting of HRAS, KRAS and NRAS, represent the most frequently mu...
The RAS gene family is frequently mutated in human cancers, and the quest for compounds that bind to...
The RAS gene family is frequently mutated in human cancers, and the quest for compounds that bind to...
Constitutively active mutant KRas displays a reduced rate of GTP hydrolysis via both intrinsic and G...
AbstractThree decades after identification of the Ras oncogene, no effective treatments for Ras muta...
Somatic mutations in the small GTPase K-Ras are the most common activating lesions found in human ca...
Ral (Ras-like) GTPases are directly activated by oncogenic Ras GTPases. Mutant K-Ras (G12C) has enab...
SummaryRas GTPases regulate intracellular signaling involved in cell proliferation. Elevated Ras sig...
Despite more than three decades of intense effort, no anti-Ras therapies have reached clinical appli...
Covalent inhibitors of K-Ras(G12C) have been reported that exclusively recognize the GDP state. Here...
Ras is at the hub of signal transduction pathways controlling cell proliferation and survival. Its m...
Mutations in RAS are associated with many different cancers, and RAS has been a therapeutic target f...
Undruggability of RAS proteins has necessitated alternative strategies for the development of effect...
The activity of Ras is controlled by the inter-conversion between GTP- and GDP-bound forms, partly r...
The small GTPase K-Ras is the most frequently mutated oncogene in cancer, and its high nucleotide af...
The RAS family of small GTPases, consisting of HRAS, KRAS and NRAS, represent the most frequently mu...
The RAS gene family is frequently mutated in human cancers, and the quest for compounds that bind to...
The RAS gene family is frequently mutated in human cancers, and the quest for compounds that bind to...